The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC CLL 2026 | Assessing treatment responses and long-term outcomes in CLL
Talha Munir, MBBS, MRCP, FRCPath, PhD, Leeds Teaching Hospitals NHS Trust, Leeds, UK, discusses a session on the assessment of treatment responses in chronic lymphocytic leukemia (CLL), highlighting the impact of various therapies and combinations on response variability. Dr Munir notes that the session will explore how short-term endpoints can serve as surrogates for improvements in long-term outcomes. This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This session is primarily looking at how we are checking the responses in our CLL patients. CLL is a chronic condition. It also is affected by the type of therapy we’re using, the combinations we are using, and as a result of that, the responses can vary between different types of therapies that we are using at this moment in time. How can we amalgamate all of that to make it a representation for all the trials that we’ve done in the past and now? And how does the new analysis of early markers of deep responses can translate into long-term outcomes which are better for our patients...
This session is primarily looking at how we are checking the responses in our CLL patients. CLL is a chronic condition. It also is affected by the type of therapy we’re using, the combinations we are using, and as a result of that, the responses can vary between different types of therapies that we are using at this moment in time. How can we amalgamate all of that to make it a representation for all the trials that we’ve done in the past and now? And how does the new analysis of early markers of deep responses can translate into long-term outcomes which are better for our patients. This is something that we will discuss in the session and obviously I will be talking about minimal residual disease but at the same time we will be talking about other overall responses that we are looking at our patients. So one of the main questions really is that can we use short-term endpoints which can be a surrogate for a long-term outcome improvement for our patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
